{
  "bio": [
    "Park Soon-jae is cofounder and CEO of South Korean biotechnology company Alteogen, which focuses on biosimilars and bio-betters.",
    "In recent years, Alteogen has been making more money from ALT-B4, a technology that allows drugs to be administered subcutaneously instead of intravenously.",
    "In February 2024, Alteogen revealed Merck had agreed to a licensing deal to use ALT-B4 for the drug giant's cancer drug pembrolizumab. Alteogen shares soared 25% in a day following the announcement.",
    "Park's wife, Chung Hye-shin, who is chief scientific officer of Alteogen, owns a small stake in the company."
  ],
  "about": [
    "Prior to cofounding Alteogen in 2008, Park worked at LG Life Sciences and Hanwha Petrochemical, and was a postdoctoral researcher at MIT."
  ]
}